Cargando…

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework

AIM: The Papilloplex high-risk human papillomavirus (hrHPV) test (Genefirst, Oxford, UK) is a single tube real-time HPV test which provides multiplex detection and separate identification of 14 hrHPV types. Here, we present the clinical validation of the test in SurePath samples in comparison to a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatia, Ramya, Alcaniz Boada, Elia, Bonde, Jesper Hansen, Quint, Wim G V, Xu, Lan, Ejegod, Ditte Moller, Cuschieri, Kate, Arbyn, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985714/ https://www.ncbi.nlm.nih.gov/pubmed/34782423 http://dx.doi.org/10.1136/jclinpath-2021-207864

Ejemplares similares

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework
por: Bonde, Jesper Hansen, et al.
Publicado: (2020)

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening
por: Ejegod, Ditte Møller, et al.
Publicado: (2020)

Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework
por: Dhillon, Sharonjit K., et al.
Publicado: (2022)

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework
por: Dhillon, Sharonjit K., et al.
Publicado: (2021)

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system
por: Bonde, Jesper, et al.
Publicado: (2014)

Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study
por: Ejegod, Ditte Møller, et al.
Publicado: (2015)

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel
por: Polman, N. J., et al.
Publicado: (2017)

Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay
por: Preisler, Sarah, et al.
Publicado: (2013)

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework
por: Xu, Lan, et al.
Publicado: (2018)

The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
por: Ejegod, Ditte, et al.
Publicado: (2016)

Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening
por: Rebolj, Matejka, et al.
Publicado: (2014)

Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening
por: Ejegod, Ditte Møller, et al.
Publicado: (2018)

Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study
por: Preisler, Sarah, et al.
Publicado: (2016)

Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays
por: Rebolj, Matejka, et al.
Publicado: (2016)

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above
por: Rebolj, Matejka, et al.
Publicado: (2016)

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016)

Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway—PaVDaG study)
por: Stanczuk, Grazyna, et al.
Publicado: (2016)

Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program
por: Ejegod, Ditte Møller, et al.
Publicado: (2021)

Human papillomavirus self‐sampling for screening nonattenders: Opt‐in pilot implementation with electronic communication platforms
por: Lam, Janni Uyen Hoa, et al.
Publicado: (2017)

Can HPV Selfy be considered as a clinically validated HPV test for use in cervical cancer screening?
por: Arbyn, Marc, et al.
Publicado: (2022)

FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years
por: Vink, Frederique J, et al.
Publicado: (2022)

Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review
por: Bonde, Jesper, et al.
Publicado: (2020)

Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019)

Diversity of cervicovaginal human papillomavirus (HPV) genotypes and naturally occurring E6/E7 DNA polymorphisms of HPV-16 in Ghana
por: Kaba, Gladys, et al.
Publicado: (2023)

Molecular characterization of high-risk human papillomavirus (HR-HPV) in women in Lomé, Togo
por: Kuassi-Kpede, Akouélé P., et al.
Publicado: (2021)

Methylation markers FAM19A4 and miR124‐2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study
por: Bonde, Jesper, et al.
Publicado: (2020)

Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda
por: Sinayobye, Jean d’Amour, et al.
Publicado: (2014)

High-risk Human Papillomavirus (hrHPV) Prevalence and Genotype Distribution among Turkish Women
por: Gecer, Melin
Publicado: (2023)

Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme
por: Dombrowski, Caroline A., et al.
Publicado: (2022)

Human Papillomavirus Genotype Distribution in Czech Women and Men with Diseases Etiologically Linked to HPV
por: Tachezy, Ruth, et al.
Publicado: (2011)

Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation
por: Weston, Georgie, et al.
Publicado: (2020)

Intra‐ and inter‐laboratory agreement of the FAM19A4/mir124‐2 methylation test: Results from an international study
por: Floore, Arno, et al.
Publicado: (2019)

High-Risk Human Papillomavirus (HR-HPV) DNA Detection in Mouthwashes for Diagnosis of HPV-Driven Oropharynx Cancer and Its Curative Therapy—A Feasibility Study
por: Loermann, Gera, et al.
Publicado: (2022)

Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee
por: Taumberger, Nadja, et al.
Publicado: (2022)

Prevalence of High-Risk Human Papillomavirus (HR-HPV) Genotypes and Multiple Infections in Cervical Abnormalities from Northern Xinjiang, China
por: Wang, Lina, et al.
Publicado: (2016)

National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study
por: Smith, Megan A, et al.
Publicado: (2022)

Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders
por: Lam, J. U. H., et al.
Publicado: (2017)

Implication of high risk Human papillomavirus HR-HPV infection in prostate cancer in Indian population- A pioneering case-control analysis
por: Singh, Neha, et al.
Publicado: (2015)

Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis
por: Mena, Marisa, et al.
Publicado: (2019)

HR Explorer
por: Möller, M, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_c2o42oc6ofmr2jiuu7v01d1oh4